Fact Meets Function

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

Researchers investigated liposomes as delivery vehicles for GHK-Cu tripeptide to improve its cosmetic application potential through in vitro studies. The research evaluated how liposome formulations could enhance the stability and penetration of GHK-Cu, a copper-containing peptide used in skincare products. This was an in vitro study examining formulation properties rather than human or animal testing.

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Read Post »

Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials.

This review article examined randomized controlled trials investigating methylene blue and its derivatives as potential treatments for Alzheimer’s disease, synthesizing evidence from human clinical trials. The review identified that methylene blue demonstrates some cognitive benefits in Alzheimer’s patients, though results across trials showed variable efficacy and the optimal dosing and formulation remain unclear. Evidence level: Human clinical trials (via systematic review).

Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials. Read Post »

Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells.

This in vitro and animal model study investigated how a glycyl-L-histidyl-L-lysine-copper (GHK-Cu) tripeptide complex affects airway remodeling in ovalbumin-sensitized mice by activating the SIRT1 pathway in airway epithelial cells. The researchers found that GHK-Cu treatment reduced airway remodeling markers, including decreased collagen deposition and smooth muscle thickening, through SIRT1 activation in epithelial cells. The evidence level is animal model and in vitro research, not human clinical evidence.

Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells. Read Post »

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.

This review article examines the melanocortin system’s role in inflammatory bowel disease (IBD) pathogenesis, exploring how melanocortin receptors and their peptide ligands—including the tripeptide KPV—modulate intestinal inflammation through immune cell regulation and barrier function (review of human clinical, animal model, and in vitro evidence). The authors discuss mechanisms by which melanocortin signaling reduces pro-inflammatory cytokine production and promotes mucosal healing, alongside current understanding of therapeutic applications in IBD management. The evidence level is mixed, synthesizing findings from human clinical studies, animal models, and in vitro experiments to characterize the melanocortin system’s therapeutic potential.

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Read Post »

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

Researchers investigated whether SLU-PP-332, a synthetic agonist targeting estrogen-related receptors (ERRα/β/γ), could induce exercise-like metabolic responses in humans. The study found that SLU-PP-332 activated ERRα-dependent pathways that mimicked acute aerobic exercise responses and improved exercise capacity in human subjects. This is human clinical evidence demonstrating pharmacological activation of metabolic pathways associated with exercise adaptation.

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. Read Post »

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation across multiple centers in healthy middle-aged adults using dose-dependent treatment groups. The study assessed both safety outcomes and efficacy measures, with findings specific to how NMN supplementation affected the study population at varying doses. This evidence represents a human clinical trial, the highest level of evidence for establishing effects in human populations.

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Read Post »

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions.

This human clinical study examined nicotinamide mononucleotide (NMN) as a potential intervention for anti-aging, longevity, and chronic disease management by investigating its effects on cellular metabolism and age-related conditions. The research found that NMN demonstrated effects on NAD+ metabolism pathways associated with aging processes and chronic disease states. This evidence is classified as human clinical research.

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Read Post »

“Drug-Carrier” Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly.

Researchers investigated a biomimetic lipid nanocomposite delivery system combining methylene blue (the active agent) with a carrier component designed to address two hallmarks of Alzheimer’s disease pathology: amyloid-β accumulation and tau phosphorylation (in vitro and animal model studies). The nanocomposite demonstrated enhanced clearance of amyloid-β and reduced tau phosphorylation compared to methylene blue alone, suggesting synergistic effects from the drug-carrier combination. **Evidence level: Preclinical (in vitro and animal model).**

“Drug-Carrier” Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly. Read Post »

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.

Researchers developed a double-network hydrogel designed to deliver KPV (a tripeptide derived from α-melanocyte-stimulating hormone) to the colon in an animal model of inflammatory bowel disease, demonstrating that the hydrogel improved markers of mucosal barrier function and reduced inflammation in inflamed colon tissue. The hydrogel formulation was engineered to provide sustained KPV release and enhanced adhesion to the intestinal mucosa compared to free KPV alone. **Evidence level: Animal model**

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Read Post »

Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns.

This review article examined nicotinamide mononucleotide (NMN) as a potential anti-aging intervention, evaluating both its proposed benefits and safety profile across available evidence. The authors identified promises in preclinical models and limited human data regarding metabolic and cardiovascular effects, while also highlighting gaps in long-term safety data and regulatory oversight for NMN as a commercial health product. This is a **review article** synthesizing existing literature rather than original human clinical research.

Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. Read Post »

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

This human clinical study describes the design and dose selection rationale for a Phase 3 randomized controlled trial of hydromethylthionine mesylate (a methylene blue derivative), an oral tau aggregation inhibitor being investigated for Alzheimer’s disease treatment. Researchers selected a 16 mg/day dose based on prior pharmacokinetic, safety, and efficacy data from earlier phase trials, with the goal of inhibiting tau protein aggregation while maintaining tolerability. The article presents the scientific basis and trial design rather than reporting primary efficacy outcomes from the Phase 3 trial itself.

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. Read Post »

Scroll to Top